Logo
x

Search category

Subscribe Now

Partner

Formycon with its Partner BIOEQ Plans to Initiate P-III MAGELLAN-AMD Trial for its FYB203 (biosimilar- aflibercept)

Formycon with its Partner BIOEQ Plans to Initiate P-III MAGELLAN-AMD Trial for its FYB203 (biosimilar- aflibercept)

  • August 24, 2020
Formycon with its Partner BIOEQ Plans to Initiate P-III MAGELLAN-AMD Trial for its FYB203 (biosimilar- aflibercept)

Formycon with its Partner BIOEQ Plans to Initiate P-III MAGELLAN-AMD Trial for its FYB203 (biosimilar- aflibercept)

  • August 24, 2020
Pfizer with its Partner BioNTech Receives the US FDA's Fast Track Designation for Two mRNA Based Therapies to Treat COVID-19

Pfizer with its Partner BioNTech Receives the US FDA's Fast Track Designation for Two mRNA Based Therapies to Treat COVID-19

  • July 13, 2020
Pfizer with its Partner BioNTech Receives the US FDA's Fast Track Designation for Two mRNA Based Therapies to Treat COVID-19

Pfizer with its Partner BioNTech Receives the US FDA's Fast Track Designation for Two mRNA Based Therapies to Treat COVID-19

  • July 13, 2020
Regeneron with its Partner NIAID Report the Initiation of P-III Trial to Evaluate REGN-COV2 for Treatment and Prevention of COVID-19

Regeneron with its Partner NIAID Report the Initiation of P-III Trial to Evaluate REGN-COV2 for Treatment and Prevention of COVID-...

  • July 6, 2020
Regeneron with its Partner NIAID Report the Initiation of P-III Trial to Evaluate REGN-COV2 for Treatment and Prevention of COVID-19

Regeneron with its Partner NIAID Report the Initiation of P-III Trial to Evaluate REGN-COV2 for Treatment and Prevention of COVID-...

  • July 6, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.